New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
Y Terauchi, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose, Y Terauchi, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose
Abstract
Aims: To compare the efficacy and safety of insulin glargine 300 U/ml (Gla-300) with glargine 100 U/ml (Gla-100) in Japanese people with type 2 diabetes using basal insulin plus oral antihyperglycaemic drug(s) [OAD(s)].
Methods: The EDITION JP 2 study (NCT01689142) was a 6-month, multicentre, open-label, phase III study. Participants (n = 241, male 61%, mean diabetes duration 14 years, mean weight 67 kg, mean body mass index 25 kg/m(2), mean glycated haemoglobin (HbA1c) 8.02 %, mean basal insulin dose 0.24 U/kg/day) were randomized to Gla-300 or Gla-100, while continuing OAD(s). Basal insulin was titrated to target fasting self-monitored plasma glucose 4.4-5.6 mmol/l. The primary efficacy endpoint was HbA1c change over 6 months. Safety endpoints included hypoglycaemia and weight change.
Results: Gla-300 was non-inferior to Gla-100 for HbA1c reduction [least squares (LS) mean difference 0.10 (95% confidence interval [CI] -0.08, 0.27) %]. The mean HbA1c at month 6 was 7.56 and 7.52 % with Gla-300 and Gla-100, respectively. Nocturnal confirmed (≤3.9 mmol/l) or severe hypoglycaemia risk was 38% lower with Gla-300 versus Gla-100 [relative risk 0.62 (95% CI 0.44, 0.88)]; annualized rates were 55% lower at night [rate ratio 0.45 (95% CI 0.21, 0.96)] and 36% lower at any time [24 h; rate ratio 0.64 (95% CI 0.43, 0.96)]. Severe hypoglycaemia was infrequent. A significant between-treatment difference in weight change favoured Gla-300 [LS mean difference -1.0 (95% CI -1.5, -0.5) kg; p = 0.0003]. Adverse event rates were comparable between groups.
Conclusions: Japanese people with type 2 diabetes using basal insulin plus OAD(s) experienced less hypoglycaemia with Gla-300 than with Gla-100, while glycaemic control did not differ.
Keywords: basal insulin; glycaemic control; insulin analogues; phase III study; randomized trial; type 2 diabetes.
© 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Figures
References
- American Diabetes Association . Standards of Medical Care in Diabetes – 2015. 7. Approaches to glycemic treatment. Diabetes Care 2015; 38: S41–S48.
- Polonsky WH, Fisher L, Guzman S, Villa‐Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543–2545.
- Peyrot M, Barnett AH, Meneghini LF, Schumm‐Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29: 682–689.
- Mukai N, Doi Y, Ninomiya T et al. Trends in the prevalence of type 2 diabetes and prediabetes in community‐dwelling Japanese subjects: the Hisayama Study. J Diabetes Investig 2014; 5: 162–169.
- Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705–716.
- Kishida K, Funahashi T, Shimomura I. Clinical importance of assessment of type 2 diabetes mellitus with visceral obesity. A Japanese perspective. Curr Diabetes Rev 2012; 8: 84–91.
- Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011; 13(Suppl. 1): S5–S14.
- Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 −1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 −1 . Diabetes Care 2015; 38: 637–643.
- Shiramoto M, Eto T, Irie S et al. Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015; 17: 254–260.
- Riddle MC, Bolli GB, Zieman M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal and mealtime insulin: glucose and hypoglycemia in a 6‐month randomized controlled trial (EDITION I). Diabetes Care 2014; 37: 2755–2762.
- Yki‐Järvinen H, Bergenstal RM, Zieman M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6‐month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235–3243.
- Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17: 386–394.
- Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with Type 1 diabetes: a randomized, phase 3a, open‐label clinical trial (EDITION 4). Diabetes Care 2015; 38: 2217–2225.
- Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T. New insulin glargine 300 U/mL: glycemic control and hypoglycaemia in Japanese people with type 1 diabetes mellitus (EDITION JP 1). Diabetologia 2014; 57: S400.
- ICH . ICH harmonized tripartite guideline: Guideline for Good Clinical Practice E6 (R1), 1996.
- World Medical Association . Declaration of Helsinki. Ethical principles for medical research involving human subjects, 2013.
- ADA Workgroup on Hypoglycemia . Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245–1249.
- Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin‐naive patients with type 2 diabetes: a 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial. J Diabetes Investig 2013; 4: 605–612.
- Suzuki D, Toyoda M, Kondo M et al. Efficacy of long‐acting insulin analog insulin glargine at high dosage for basal‐bolus insulin therapy in patients with type 2 diabetes. Tokai J Exp Clin Med 2012; 37: 35–40.
- Oishi M, Abe N, Yokoyama H et al. Observational 6‐month open‐label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal‐bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23). J Int Med Res 2012; 40: 787–797.
- Saisho Y. Obesity, type 2 diabetes and beta cell failure: an Asian perspective. J Mol Genet Med 2014; S1: 008.
- Arai K, Matoba K, Hirao K et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross‐sectional survey of 15,652 patients. Endocr J 2010; 57: 499–507.
- Karl DM, Gill J, Zhou R, Riddle MC. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 622–628.
- Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319–328.
Source: PubMed